All stock lists
Annovis Bio, Inc. (New York Stock Exchange:ANVS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
0.84+0.18 (+26.31%)
Market cap
$36.1M
Insider Score
Health Score
Analyst consensus
Listed since
Jan 29, 2020
Website
Insider Score
56/ 100
ANVS Insider Score
Bullish1 qualifying trade · 1 insider · $5.00M bought in the last 90 days
Financial Health Score
Fair
From ANVS’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$49.5M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $18.7M
- Total debt
- $0
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $18.7M
- Current liabilities
- $6.4M
- Current ratio
- 2.95
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$43.3M
- Free cash flow
- -$43.3M
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 37.5M
- Share growth (1y)
- 92.5%
- Cash runway
- 5 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ANVS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 2.37 B | 1.29 B | 955.15 K | 1.14 M | 1.11 M | 1.27 M |
| R&D Expense | 12.01 B | 16.72 B | 8.75 M | 6.29 M | 5.16 M | 5.01 M |
| Operating Expenses | 14.38 M | 18.01 M | 9.71 M | 7.43 M | 6.27 M | 6.28 M |
| Operating Income | -14.38 M | -18.01 M | -9.71 M | -7.43 M | -6.27 M | -6.28 M |
| Pretax Income | -14.82 M | -17.61 M | -9.83 M | -7.26 M | -6.22 M | -5.54 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -14.82 M | -17.61 M | -9.83 M | -7.26 M | -6.22 M | -5.54 M |
| EPS (Basic) | -0.39 | -0.63 | -0.40 | -0.37 | -0.32 | -0.32 |
| EPS (Diluted) | -0.39 | -0.63 | -0.40 | -0.37 | -0.32 | -0.32 |
| Shares Outstanding | 37.52 M | 27.85 M | 24.81 M | 19.69 M | 19.49 M | 17.43 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.